Birth in the neonatal HBV vaccination era and hepatitis B surface antigen seroclearance in people with HIV and HBV coinfection on tenofovir-containing antiretroviral therapy

Clicks: 2
ID: 320767
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal

Ranked #288 of 530 articles by views in Clinical infectious diseases : an official publication of the Infectious Diseases Society of America

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 530 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
BACKGROUND: The impact of long-term tenofovir-containing antiretroviral therapy (ART) on hepatitis B surface antigen (HBsAg) seroclearance in people with HIV (PWH) and HBV coinfection remains under-defined, particularly in HBV-hyperendemic regions with universal vaccination programs. METHODS: HBsAg-positive PWH receiving tenofovir-containing ART between 2011 and 2023 were followed until December, 2025. Demographics, HBV serologic markers, plasma HBV DNA, and liver fibrosis stage were collected. Cox proportional hazards models were used to identify factors associated with HBsAg seroclearance. Clinical and hepatic outcomes were compared by seroclearance status. RESULTS: After a median follow-up of 9.4 years, 35 (8.4%) of 415 PWH achieved HBsAg seroclearance during a total of 3,600 person-years of tenofovir-containing ART, corresponding to an incidence rate of 0.97 per 100 person-years. Among them, 37.1% (13/35) tested positive for anti-HBs at the time of seroclearance. In multivariable analysis, birth in universal neonatal HBV vaccination era (after July 1986) (adjusted hazard ratio [aHR] 13.56, 95% confidence interval [CI] 6.08-30.28, P<0.001), baseline HBsAg ≤250 IU/mL (aHR 7.36, 95% CI 3.29-16.50, P<0.001), and higher baseline ALT level (aHR 1.00 per 1-U/L increase, 95% CI 1.00-1.01, P<0.001) were independently associated with HBsAg seroclearance. None of PWH who achieved HBsAg seroclearance developed seroreversion, cirrhosis, or hepatocellular carcinoma, whereas 6.6% and 2.1% of PWH without seroclearance developed cirrhosis and hepatocellular carcinoma, respectively. CONCLUSIONS: Despite long-term tenofovir-containing ART, HBsAg seroclearance was uncommon (0.97% annually) among PWH with HBV coinfection. Birth in the neonatal HBV vaccination era and lower baseline HBsAg level were two independent predictors of HBsAg seroclearance.
Reference Key
openalex_W7168104446 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Yu‐Shan Huang, Hsin‐Yun Sun, Kuan‐Yin Lin, Sung‐Hsi Huang, Yi‐Chia Huang, W H Liu, Guan‐Jhou Chen, Kai-Hsiang Chen, Li‐Hsin Su, Yi-Ching Su, W H Liu, Sui‐Yuan Chang, Chien‐Ching Hung
Journal Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
Year 2026
DOI
10.1093/cid/ciag429
URL
https://doi.org/10.1093/cid/ciag429
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.